Take­da wins long-await­ed US ap­proval for first oral drug for eosinophilic esophagi­tis

The FDA on Mon­day ap­proved Take­da’s Eo­hil­ia, the first oral drug for pa­tients with eosinophilic esophagi­tis (EoE) in the US, which the com­pa­ny briefly aban­doned af­ter re­ceiv­ing a com­plete re­sponse let­ter.

Take­da will now have to com­pete with Sanofi and Re­gen­eron’s block­buster Dupix­ent, which won its ex­pand­ed ap­proval in EoE in 2022. EoE caus­es in­flam­ma­tion of the esoph­a­gus, lead­ing to vom­it­ing, dif­fi­cul­ty swal­low­ing and pain.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.